Weinberger Daniel M, Warren Joshua L, Steiner Claudia A, Charu Vivek, Viboud Cécile, Pitzer Virginia E
Department of Epidemiology of Microbial Disease.
Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut.
Clin Infect Dis. 2015 Aug 15;61(4):506-14. doi: 10.1093/cid/civ331. Epub 2015 Apr 22.
Respiratory syncytial virus (RSV) is a major cause of respiratory infections among young children and can lead to severe disease among some infants. Infants at high risk for severe RSV infection receive monthly injections of a prophylactic monoclonal antibody during the RSV season based on national guidelines. We considered whether a reduced-dose schedule tailored to the local RSV season in the continental United States would provide adequate protection.
Hospitalization data for 1942 counties across 38 states from 1997 to 2009 were obtained from the State Inpatient Databases (Agency for Healthcare Research and Quality). We assessed the timing of RSV epidemics at the county and state levels using a 2-stage hierarchical Bayesian change point model. We used a simple summation approach to estimate the fraction of RSV cases that occur during the window of protection provided by initiating RSV prophylaxis during different weeks of the year.
The timing of RSV epidemic onset varied significantly at the local level. Nevertheless, the national recommendations for initiation of prophylaxis provided near-optimal coverage of the RSV season in most of the continental United States. Reducing from 5 to 4 monthly doses (with a later initiation) provides near-optimal coverage (<5% decrease in coverage) in most settings. Earlier optimal dates for initiating 4 doses of prophylaxis were associated with being farther south and east, higher population density, and having a higher percentage of the population that was black or Hispanic.
A 4-dose schedule of prophylactic injections timed with local RSV epidemics could provide protection comparable to 5 doses and could be considered as a way to improve the cost-effectiveness of prophylaxis.
呼吸道合胞病毒(RSV)是幼儿呼吸道感染的主要病因,可导致部分婴儿出现严重疾病。根据国家指南,重度RSV感染高危婴儿在RSV流行季节每月注射一剂预防性单克隆抗体。我们探讨了根据美国大陆当地RSV流行季节量身定制的减少剂量方案是否能提供足够的保护。
从州住院数据库(医疗保健研究与质量局)获取了1997年至2009年38个州1942个县的住院数据。我们使用两阶段分层贝叶斯变化点模型评估了县和州层面RSV流行的时间。我们采用简单求和方法来估计在一年中不同周开始进行RSV预防所提供的保护期内发生的RSV病例所占比例。
RSV流行开始的时间在地方层面差异显著。尽管如此,全国性的预防起始建议在美国大陆大部分地区提供了接近最佳的RSV流行季节覆盖范围。将每月剂量从5剂减至4剂(起始时间稍晚)在大多数情况下提供了接近最佳的覆盖范围(覆盖范围减少<5%)。开始4剂预防的较早最佳日期与更偏南和偏东、人口密度较高以及黑人或西班牙裔人口比例较高有关。
根据当地RSV流行情况安排的4剂预防性注射方案可提供与5剂相当的保护,可被视为提高预防成本效益的一种方式。